MedTrace Logo

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

NCT02064491 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-06-22

No results posted yet for this study

Summary

The purpose of this study is to determine whether continuing erlotinib beyond disease progression in combination with chemotherapy is beneficial for NSCLC patients who have EGFR mutant disease or who have responded to EGFR TKI.

Conditions

Interventions

DRUG

Erlotinib

DRUG

Chemotherapy

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Finnish Lung Cancer Group

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-12-31
Completion
2017-05-31

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02064491 on ClinicalTrials.gov